R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Bolstering CAR-T therapies by tackling CRS, with Teresa Whal...

In interview with Teresa Whalen, the CEO of CytoAgents, a clinical-stage drug development company working on a treatment for cytokine release syndrome

R&D

pharmaphorum podcast Episode 209a, Gene Mack

Allosteric small molecule therapies in PD, with Gene Mack

pharmaphorum looks back to a conversation with Gain Therapeutics' CEO Gene Mack earlier in the year, on research in the Parkinson's disease space.

R&D

How are healthy biomarker ranges defined?

What makes a biomarker a biomarker?

R&D

From pilots to patients: Why the UK must rethink NHS innovat...

At PharmaTech Integrates in Glasgow, speakers from government, academia, the NHS, and pharma sought to define the sector’s path forward.

R&D

pharmaphorum podcast Episode 207a, Brandon Pence

The importance of being disruption ready, with Brandon Pence

Brandon Pence, recently appointed President and COO of Fujifilm Biosciences, discusses the cell culture media industry and being disruption ready.

R&D

Q3 Clinical trials round-up: July to September 2025

As the third quarter of 2025 draws to a close, the clinical research landscape has been marked by a surge of promising data and regulatory milestones.